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incidence
Malignant pleural mesothelioma (MPM) is a rare tumour.
The incidence is 1.25/100 000 in Great Britain and 1.1/100 000
in Germany. Within the next 20 years the incidence is
estimated to double in many countries. Exposure to asbestos is
a well-established aetiological factor for MPM, with
occupational exposure being documented in 70%–80% of those
affected.
diagnosis
Patients typically present with shortness of breath due to
pleural effusion or chest pain in a more advanced stage. The
diagnosis is usually suggested by imaging studies (unilateral
pleural thickening; pleural effusion). An occupational history
must be obtained.
Cytological examination of the effusion can be diagnostic,
but often shows equivocal results. Therefore, histology,
including immunohistochemistry, is the gold standard.
Pleuroscopy, a video-assisted surgical procedure or open
pleural biopsy in a fused pleural space may be necessary to
provide sufficient material for accurate histological diagnosis.
There are three main histological types (epithelial, sarcomatous
and mixed) with 60% being epithelial.
Data suggest the possible contribution of serum mesothelin-
related proteins and osteopontin as useful markers to support
the diagnosis of mesothelioma; however, the precise role of
these markers is yet to be defined.
staging and risk assessment
Clinical staging is based on the CT scan of the chest. However,
the translation of the images into TNM stages is often not
conclusive. Mediastinoscopy and video-assisted thoracoscopy
may be useful in determining the stage. Accurate initial staging
is essential to provide both prognostic information and
guidance on the most appropriate therapeutic options. Several
different staging systems exist, among them the international
IMIG staging system for MPM which emphasizes the extent of
disease post-surgery in a traditional TNM system and stratifies
patients into prognostic categories similar to those shown in
Table 1.
The European Organization for Research and Treatment of
Cancer prognostic scores may be used. They include
performance status, gender, certainty of histology, histological
type and white blood count.
MPM rarely metastasizes to distant sites but most patients
present with locally advanced disease. The use of PET scan to
rule out extra-thoracic metastasis in patients considered for
radical treatment is under investigation and findings seem
promising.
treatment
surgery
Various surgical procedures have been studied with varying
degrees of success.
Extra-pleural pneumonectomy (EPP) with resection of the
hemi-diaphragm and the pericardium en bloc has the
potential for a radical treatment and this approach is
generally combined with neoadjuvant or adjuvant
chemotherapy and/or adjuvant radiotherapy. Surgery, the
appropriateness of which is still under consideration, should
only be performed on selected patients by experienced thoracic
surgeons in the context of a multidisciplinary team and
preferably as part of a clinical trial [III, A]. Selection criteria
include good performance status, and earlier stage disease with
not more than localized involvement of the thoracic wall,
and adequate cardiopulmonary function. The inclusion of
*Correspondence to: ESMO Guidelines Working Group, ESMO Head Office, Via L.
Taddei 4, CH-6962 Viganello-Lugano, Switzerland;
E-mail: clinicalrecommendations@esmo.org
Approved by the ESMO Guidelines Working Group: December 2004, last update March
2010. This publication supercedes the previously published version—Ann Oncol 2009;
20 (Suppl 4): iv73–iv75.
Conflict of interest: Professor Lievens and Dr Felip have reported no conflicts of interest.
Prof Stahel has reported that he has received honoraria from Eli Lilly for advisory boards
and speaker activity; Prof Weder has not reported any conflicts of interest.
ª The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
patients with N2 or sarcomatoid disease is controversial.
Pleurectomy/decortication may be indicated for elderly
patients, at early stages or when EPP would leave macroscopic
tumour behind.
To optimally palliate patients from dyspnea and pain, local
procedures to control pleural effusion include parietal
pleurectomy or talc pleurodesis.
radiotherapy
The use of curative intent hemithoracic radiotherapy has been
limited because of the difficulty of irradiating such a large
target volume to high doses without exceeding the tolerance of
the adjacent normal tissues, especially the (homolateral)
lung. The exact role of definitive radiotherapy in the multi-
modality approach of MPM is currently under
investigation. Nevertheless, in an attempt to improve local
control after EPP, it has been shown feasible to deliver
radiotherapy doses of >45 Gy with both 3D conformal
(3D-CRT) and intensity-modulated radiotherapy (IMRT).
However, caution must be exercised regarding the exposure of
the contralateral lung to low-dose irradiation, especially when
using IMRT [III, B].
In the palliative setting, radiotherapy can be delivered locally
in view of pain control or prevention of obstructive symptoms
[IV, C]. As mesothelioma invades the tracts made by chest
instrumentation, prophylactic irradiation to the intervention
tracts (PIT) has been advocated to reduce the incidence of port
metastases. In the absence of unambiguous prospective
data—the consequence of randomized trials with small patient
numbers, different results according to histology and highly
variable RT techniques—however, it remains impossible to
draw definitive conclusions regarding its efficacy [II, C].
chemotherapy
Platinum analogues, doxorubicin and some antimetabolites
(methotrexate, raltitrexed, pemetrexed) have shown modest
single-agent activity [III, B].
The combinations of both pemetrexed/cisplatin, and to
a smaller extent raltitrexed/cisplatin, have been shown to
improve survival as well as lung function and symptom control
in comparison with cisplatin alone in randomized trials [II, A].
The combination of pemetrexed/carboplatin is an alternative
effective therapy [III, A]
A phase III trial evaluated second-line pemetrexed versus best
supportive care in patients not previously exposed to this agent
and found a longer time to disease progression in the
chemotherapy arm. Since vinorelbine or gemcitabine have first-
line activity they might be a reasonable choice in second-line
therapy. One study on 63 patients treated with vinorelbine
reported a 16% response rate and median survival of 9.6
months [III, A].
If extrapleural pneumonectomy is planned, platinum-based
neoadjuvant or adjuvant combination chemotherapy should be
considered.
response evaluation
Response evaluation using CT scan is recommended after two
to three chemotherapy cycles and the modified RECIST criteria
should be applied. Volumetric measurements are under
investigation.
follow-up
Follow-up consists of clinical evaluation, with particular
attention to symptoms or chest wall recurrence, and chest CT
as needed.
note
Levels of Evidence [I–V] and Grades of Recommendation [A–
D] as used by the American Society of Clinical Oncology are
given in square brackets. Statements without grading were
considered justified standard clinical practice by the expert
authors and the ESMO faculty.
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